Skip to main content
Elizabeth M. Whitehorn, Director

Provider Notice issued 08/06/2026

PDL Update to Brand-name Focalin XR Capsules 

To:
 Enrolled Pharmacies, Physicians, and Advanced Practice Registered Nurses
​Re:
 PDL Update to Brand-name Focalin XR Capsules 
Date:
 August 7, 2026

This notice informs providers of an update involving Focalin XR (dexmethylphenidate extended-release) capsules on the Illinois Medicaid Preferred Drug List (PDL).

The manufacturer of brand-name Focalin XR capsules has discontinued production effective immediately. In response, the Department of Healthcare and Family Services (HFS) has designated generic dexmethylphenidate ER capsules as preferred and will continue to list brand-name Focalin XR capsules as preferred on the PDL. This change is effective as of Friday, July 24, 2026. Pharmacies may continue to dispense brand-name Focalin XR capsules until their inventory is depleted.

This change will apply to Fee-For-Service (FFS) and Managed Care Organizations (MCOs).

Questions regarding this notice may be directed to the Bureau of Professional and Ancillary Services at 877-782-5565, or the applicable MCO.

 

Laura Phelan
Administrator, Division of Medical Program